Wexford Capital’s CRISPR Therapeutics CRSP Stock Holding History

Wexford Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$64.8K	–	414
2025 Q3	$64.8K	Sell	1,000 -7,906	-89%	-$454K	0.01%	279
2025 Q2	$433K	Buy	+8,906	New	+$345K	0.12%	114
2021 Q1	–	Sell	-300	Closed	-$46K	–	234
2020 Q4	$46K	Buy	+300	New	+$35.5K	0.01%	178

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital's CRSP Position: Q4 2025 in Review

Wexford Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 1,000 shares — an estimated $64.8K sold.

Wexford Capital first reported a position in CRSP in Q4 2020 and held it in 3 quarters. The position peaked at $433K in Q2 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Wexford Capital reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Wexford Capital sold 1,000 CRISPR Therapeutics shares in Q4 2025, an estimated $64.8K.
Wexford Capital first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 3 quarters.
Wexford Capital's CRISPR Therapeutics position peaked at $433K in Q2 2025.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.